Fig. 2

Influences of DC cross-presentation and biocompatibility after labelling with SPIO. a Cross-presentation of DCs enhanced at different SPIO concentrations. b Apoptotic DCs and SPIO-labeled DCs examined by FCS at different concentrations (10, 25, 50, and 100 μg/mL). c Phenotypes of the DCs, including CD11c⁺CD80⁺ and CD11c⁺CD86⁺ after labelling with SPIO (10, 25, 50 μg/mL). DCs stimulated with LPS (1 μg/mL) were used as positive controls. d Apoptotic DCs loaded with 25 μg/mL SPIO examined by FCS at different time points (6, 12, 18, and 24 h)